Showing results (211-220 of 321) with videos related to

Sort By:
Pageof 33
Annals of the Rheumatic Diseases|February 1, 2014
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trialChristopher Ritchlin, Proton Rahman, Arthur Kavanaugh, et al.
The Journal of Rheumatology|February 15, 2023
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST ProgramAtul Deodhar, Denis Poddubnyy, Proton Rahman, et al.
Rheumatology and Therapy|April 18, 2024
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical TrialKurt de Vlam, Walter P Maksymowych, Gaia Gallo, et al.
BMC Rheumatology|February 3, 2024
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled studyLaura C Coates, Proton Rahman, Philip J Mease, et al.
Annals of the Rheumatic Diseases|February 21, 2014
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trialsArthur Kavanaugh, Christopher Ritchlin, Proton Rahman, et al.
The Journal of Rheumatology|April 17, 2009
IL-23R polymorphisms in patients with ankylosing spondylitis in KoreaIl-Hoon Sung, Tae-Hwan Kim, So-Young Bang, et al.
The Lancet. Rheumatology|January 30, 2024
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 studyLaura C Coates, William Tillett, Maria-Antonietta D'Agostino, et al.
Nature Genetics|January 27, 2009
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathwaysRajan P Nair, Kristina Callis Duffin, Cynthia Helms, et al.
Annals of the Rheumatic Diseases|March 19, 2018
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 studyPhilip Mease, Désirée van der Heijde, Robert Landewé, et al.
RMD Open|February 24, 2023
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritisAlice B Gottlieb, Iain B McInnes, Proton Rahman, et al.
Pageof 33